yes, the bigger question. I have been guessing at valuation based on about 850 million fully diluted outstanding shares. It may be closer to 1 billion when all said and done, depending on warrants and further dilution. So, given recent acquisitions of lesser (IMO) potential companies, I am looking for a 10+ billion valuation/buyout or around $10/share. That would be prior to FDA approval, but after topline release of positive data. Unfortunately, we have zero idea when that will be. 4 months past ASCO, August is past. November seems to be the next goal post to be moved based on management's prior actions, or lack thereof. IMO.
News 
Market Data 
Discover 
